Stem Cells Archives | Page 145 of 201

Cord Blood Market Trends, by Region and Sub-Segment

November 21, 2016 By Cade Hildreth, Founder & President Leave a Comment

The cord blood market is a complex international industry, composed of public, private, and hybrid cord blood banks.

These market participants store a range of varied products, including cord blood, cord tissue, and sometimes, related perinatal tissues and stem cell types. Rates of cord blood utilization for clinical use vary substantially as well.

Therefore, our approach to analyzing cord blood market trends is to look at it geographically, as well as by sub-segment according to blood units banked, tissue units banked, and clinical units transplanted.

A high level assessment of cord blood market growth is that North American is flat, North Asia and Southeast Asia (SEA) are growing by double digits, and Europe is declining.

We summarize these cord blood industry trends as follows:

Cord Blood Market Activity, by Region and Sub-Segment — *Click to expand (table courtesy of BioInformant partner, Kenneth Harris).

To learn more, read our recent interview with Kenneth Harris of CuraSense Advisors, in which we discuss growth rates and trends within the global cord blood banking industry.

What is the Most Predictive Cardiac Cell Model? FDA Publication Confirms COR.4U By Axiogenesis

November 11, 2016 By Cade Hildreth, Founder & President Leave a Comment

Two recent peer-reviewed publications underline the predictive value of Axiogenesis Cor.4U iPSC-derived cardiomyocytes (iPSC-CMs).

There was a publication earlier this year by Astra Zeneca researchers that resulted in a somewhat negative perception (mostly by iPS cell skeptics) of iPSC-derived cells. The predictive value of iPSCs was questioned, with the abstract stating, “iCell^® cardiomyocytes have limited value as an integrated QT/TdP assay, highlighting the urgent need for improved experimental alternatives that may offer an accurate integrated cardiomyocyte safety model for supporting the development of new drugs without QT/TdP effects.” [Read more…]

SanBio Granted Key Stem Cell Patent for Treatment of Traumatic Brain Injury (TBI)

November 9, 2016 By Cade Hildreth, Founder & President Leave a Comment

SanBio, a stem cell and regenerative medicine company specializing in neurological disorders, announced that it has been issued a key patent by the Australian Patent Office covering its proprietary modified stem cells, SB623, for the treatment of traumatic brain injury. Australian Patent No. 2013263417 was formally issued on September 8, 2016.

To secure its proprietary technology, SanBio filed a global patent application for it modified stem cells (SB623), doocumenting its ability to support regenerative processes in the central nervous system (CNS). The patent also documents the ability of these cells to provide therapeutic support for a range of neurological disorders, including traumatic brain injury (TBI).

Australia was the first country to grant the patent to SanBio. The company is also seeking patent protection in other regions.

According to Dr. Damien Bates, Chief Medical Officer and Head of Research at SanBio, “There are 5.3 million people living with chronic disabilities from traumatic brain injury in the United States and more than 700,000 in Australia. We hope that SanBio’s regenerative medicine, SB623, will be able to serve as a treatment option for these patients.”

Axiogenesis and Metrion Biosciences to Develop Human iPSC-derived Cardiomyocytes and Neurons

November 7, 2016 By Cade Hildreth, Founder & President Leave a Comment

Axiogenesis announced today that it will be collaborating with Metrion Biosciences to validate, optimise and commercialise iPSC-derived cell based assays to facilitate drug discovery and more accurately predict cardiac arrhythmia and neuronal risk. Metrion Biosciences a UK-based contract research organization (CRO) that is best known as an ion channel specialist.

Through this strategic partnership, Axiogenesis continues to strengthen its position within the iPS cell marketplace as a leading provider of cell-based solutions to facilitating drug discovery, safety, and toxicology applications. To learn more, see the full press release, included below with permission from Axiogenesis.

Axiogenesis is a fascinating company specializing in the development of induced pluripotent stem cells (iPSCs) and tissue types. It is the second largest iPSC company in the world after Cellular Dynamics International (CDI), in Madison, Wisconsin.

Axiogenesis was also the first European company to license and adopt Yamanaka’s iPSC technology in 2010. The company now specializes in human induced pluripotent stem cell (hiPSC) products, including in vitro models of healthy and diseased cell types and tissues.

Will I See You at the World Stem Cell Summit 2016? (Psst, Here’s a $200 Discount Code)

November 3, 2016 By Cade Hildreth, Founder & President 1 Comment

BioInformant is honored to sponsor and attend the 12th annual World Stem Cell Summit 2016being held in West Palm Beach, Florida on December 6-9, 2016, by the Regenerative Medicine Foundation.

The World Stem Cell Summit brings together more than 1,200 intelligent minds, putting brilliant speakers on stage and packing rooms with curious and eager listeners.

In my opinion, the World Stem Cell Summit is the ultimate gathering for the stem cell community.

What is the World Stem Cell Summit?

The World Stem Cell Summit is the world’s largest interdisciplinary meeting to bring together stakeholders from across the stem cell and regenerative medicine spectrum.

The key aspect that makes the World Stem Cell Summit a must-attend event is that it brings together stem cell executives, investors, researchers, clinicians, doctors, advocates, patients, and more. I can report from experience that it is extremely rare for a stem cell event to attract stakeholders from across the stem cell spectrum.

The event also features over 200 renowned speakers, which means that for the past month, I’ve been reviewing the speaker list and planning out my “must see” talks.

Last year, the 2015 event held in Atlanta, GA, attracted more than 1,200 attendees from 40+ countries. Impressively, there were up to seven different speakers presenting at any given moment, meaning the the shear volume of content being shared is incredible.

In addition to the concurrent speaker tracks, there were also Expert Luncheon Roundtables, Investor Presentations, and a “Stem Cell Actions Award Dinner.” [Read more…]